Cover Image
市場調查報告書

Mologen AG:開發中產品分析 (2015年)

Mologen AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226268
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Mologen AG:開發中產品分析 (2015年) Mologen AG - Product Pipeline Review - 2015
出版日期: 2015年10月14日 內容資訊: 英文 37 Pages
簡介

Mologen AG是從事各種傳染病、腫瘤治療藥之研究開發活動的生物科技企業。該公司的開發中產品有MGN1703和MGN1601,GN1404,MGN1331,MGN1333等。該公司同時活用MIDGE・dSLIM・EnanDIM等平台技術來開發醫藥品和疫苗。其主力產品有針對複數症狀之DNA癌症治療藥,以及預防傳染病用的DNA疫苗候補藥、癌症用細胞型治療藥等。

本報告提供德國的生物醫藥品企業──Mologen AG的醫藥品研究開發進展相關分析,提供您該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品簡介與開發情形,該公司簡介與最新趨勢等調查。

目錄

Mologen AG:基本資料

  • 企業概要
  • 主要資訊
  • 主要資料

Mologen AG:研究開發 (R&D) 活動概況

  • 主要的治療領域

Mologen AG:開發平台評估

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥

Mologen AG:開發中產品概要

  • 後期階段的開發中產品
    • 第三階段產品/並用治療方法
  • 臨床實驗階段的開發中產品
    • 第二階段產品/並用治療方法
    • 第一階段產品/並用治療方法
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療方法

Mologen AG:藥物簡介

  • MGN-1703
    • 產品概要
    • 作用機制
    • 研究開發 (R&D) 的發展
  • MGN-1601
  • MGN-1404
  • MGN-1331
  • MGN-1333
  • 感染疾病·腫瘤TLR-9活躍用寡核甘酸

Mologen AG:開發平台分析

  • 標的別
  • 各投藥法
  • 各分子類型
  • 各作用機制

Mologen AG:開發中產品的最新趨勢

Mologen AG:暫停的計劃

Mologen AG:公司所在地及子公司

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07658CDB

Summary

Global Markets Direct's, 'Mologen AG - Product Pipeline Review - 2015', provides an overview of the Mologen AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mologen AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mologen AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mologen AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mologen AG's pipeline products

Reasons to buy

  • Evaluate Mologen AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mologen AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mologen AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mologen AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mologen AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mologen AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mologen AG Snapshot
    • Mologen AG Overview
    • Key Information
    • Key Facts
  • Mologen AG - Research and Development Overview
    • Key Therapeutic Areas
  • Mologen AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Mologen AG - Pipeline Products Glance
    • Mologen AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Mologen AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Mologen AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Mologen AG - Drug Profiles
    • MGN-1703
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-1601
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-1404
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-1331
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-1333
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Activate TLR-9 for Infectious Disease and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mologen AG - Pipeline Analysis
    • Mologen AG - Pipeline Products by Target
    • Mologen AG - Pipeline Products by Route of Administration
    • Mologen AG - Pipeline Products by Molecule Type
    • Mologen AG - Pipeline Products by Mechanism of Action
  • Mologen AG - Recent Pipeline Updates
  • Mologen AG - Dormant Projects
  • Mologen AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mologen AG, Key Information
  • Mologen AG, Key Facts
  • Mologen AG - Pipeline by Indication, 2015
  • Mologen AG - Pipeline by Stage of Development, 2015
  • Mologen AG - Monotherapy Products in Pipeline, 2015
  • Mologen AG - Phase III, 2015
  • Mologen AG - Phase II, 2015
  • Mologen AG - Phase I, 2015
  • Mologen AG - Preclinical, 2015
  • Mologen AG - Pipeline by Target, 2015
  • Mologen AG - Pipeline by Route of Administration, 2015
  • Mologen AG - Pipeline by Molecule Type, 2015
  • Mologen AG - Pipeline Products by Mechanism of Action, 2015
  • Mologen AG - Recent Pipeline Updates, 2015
  • Mologen AG - Dormant Developmental Projects,2015

List of Figures

  • Mologen AG - Pipeline by Top 10 Indication, 2015
  • Mologen AG - Pipeline by Stage of Development, 2015
  • Mologen AG - Monotherapy Products in Pipeline, 2015
  • Mologen AG - Pipeline by Top 10 Target, 2015
  • Mologen AG - Pipeline by Top 10 Route of Administration, 2015
  • Mologen AG - Pipeline by Top 10 Molecule Type, 2015
  • Mologen AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top